Myriad Genetics Inc
(NQ:
MYGN
)
28.33
+0.01 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
883,549
Open
28.36
Bid (Size)
28.33 (3)
Ask (Size)
29.78 (1)
Prev. Close
28.32
Today's Range
27.84 - 28.97
52wk Range
13.82 - 29.08
Shares Outstanding
90,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
Via
Investor's Business Daily
Performance
YTD
+49.11%
+49.11%
1 Month
+2.64%
+2.64%
3 Month
+26.76%
+26.76%
6 Month
+28.95%
+28.95%
1 Year
+57.21%
+57.21%
More News
Read More
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
August 13, 2024
Via
Benzinga
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Key Takeaways From Myriad Genetics Analyst Ratings
June 27, 2024
Via
Benzinga
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Avantor Stock Earns 84 RS Rating
July 30, 2024
Via
Investor's Business Daily
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Via
InvestorPlace
Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
June 24, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
June 18, 2024
Via
MarketBeat
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
June 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
June 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
May 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
May 10, 2024
Via
InvestorPlace
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 08, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.